Related references
Note: Only part of the references are listed.B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction
Christiane S. Tudor et al.
HUMAN PATHOLOGY (2013)
Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
Paul Greaves et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma
Luigi Panico et al.
LEUKEMIA & LYMPHOMA (2013)
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Yvette L. Kasamon et al.
BLOOD (2012)
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
Sharon M. Castellino et al.
BLOOD (2011)
Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
Christian Steidl et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
Brad H. Nelson
JOURNAL OF IMMUNOLOGY (2010)
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Circulating clonotypic B cells in classic Hodgkin lymphoma
Richard J. Jones et al.
BLOOD (2009)
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
Bruno Chetaille et al.
BLOOD (2009)
Hodgkin Lymphoma: An Update on its Biology with New Insights into Classification
Haresh Mani et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
Yasuhiro Oki et al.
CANCER (2008)
The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression
Todd W. Kelley et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Abel Sanchez-Aguilera et al.
BLOOD (2006)
Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells
T Alvaro et al.
CLINICAL CANCER RESEARCH (2005)
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
A Younes et al.
CANCER (2003)
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma
D Molin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Long-term follow-up of Hodgkin's disease trial
GP Canellos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression profiling defines molecular subtypes of classical Hodgkin's disease
E Devilard et al.
ONCOGENE (2002)
Hodgkin's lymphoma: the pathologist's viewpoint
SA Pileri et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Share Paper
